Announcements Trials
Browse Landscape

Status

Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Urinary Bladder Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

balstilimab 2zipalertinib 1tisagenlecleucel 1telisotuzumab vedotin 1ribociclib 1nirogacestat 1mirdametinib 1mifamurtide 1lifileucel 1leronlimab 1gallium maltolate 1futibatinib 1fluorodopa F 18 1dodecyl maltoside 1ceritinib 1carbon-11 methionine 1capmatinib 1brexucabtagene autoleucel 1Sunitinib 1Methionine 1Alpelisib 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × dodecyl maltoside × 90 days × Clear all
NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

CG Oncology, Inc.

Available
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡